Included Health Appoints Mark Flakne as Chief Financial Officer
Key Highlights Mark Flakne named CFO of Included Health, bringing over 20 years of experience. Former CFO of OptumHealth where…
Halda Therapeutics Secures $126M to Advance Novel RIPTAC Cancer Therapies
Key Highlights Halda Therapeutics raises $126M in Series B extension, total $202M funding to date. Proceeds will advance…
Velia Therapeutics Appoints Dr. Alan Saghatelian as Chief Technology Officer
Key Highlights Dr. Alan Saghatelian named Chief Technology Officer at Velia Therapeutics. Scientific co-founder with over 25 years…
Dr. Sara Q. Perkins Joins Central Ohio Urology Group’s Award-Winning Team
Key Highlights Dr. Sara Q. Perkins joins Central Ohio Urology Group, bringing expertise in robotic surgery and personalized urologic…
Create Health Ventures Closes $21M Fund to Back Early-Stage Digital Health Startups
Key Highlights $21 million fund closed by Create Health Ventures, targeting digital health startups. Focus on B2B solutions that enhance…
Quantum Health Appoints Dr. Stanley Crittenden as Chief Medical Officer
Key Highlights Dr. Stanley Crittenden named Chief Medical Officer of Quantum Health. Will lead clinical strategy, including Utilization…
Paige and Microsoft Unveil Virchow2: A Groundbreaking AI Model for Cancer Diagnosis
Key Highlights Virchow2 and Virchow2G: Largest AI models in clinical pathology with 1.8 billion parameters. Collaboration with Microsoft:…
Amy K. McCarthy Joins Hippocratic AI as Inaugural Chief Nursing Officer
Key Highlights Amy K. McCarthy appointed as inaugural Chief Nursing Officer at Hippocratic AI. McCarthy to lead initiatives on AI integration…
Innovaccer Launches Government Health AI Data and Analytics Platform
Key Highlights Innovaccer launches GHAAP to tackle data fragmentation in government health organizations. Platform integrates clinical and non-clinical data to…
Merck to Acquire CN201, Expanding B-cell Disease Treatment Pipeline
Key Highlights Merck to acquire CN201, a clinical-stage bispecific antibody targeting B-cell diseases. Transaction valued at $700M upfront,…